Targeted microbubble for sensitizing high-intensity focused ultrasound and application thereof

Through targeted microvesicle enhanced ultrasound imaging and HIFU treatment, the problem of incomplete ablation of deep tumors and normal tissue damage was solved, achieving more efficient liver cancer treatment and immune response activation.

CN119074957APending Publication Date: 2024-12-06CHONGQING MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411258750.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

During HIFU treatment, deep or blood-rich tumors are difficult to completely ablate, and high-power ultrasound may damage normal tissue and poor ultrasound imaging quality.

Method used

A targeted microvesicle was developed, made from lipid shells of polyethylene glycol, phospholipids and fatty acids filled with perfluorobutane and incubated with biotinylated antibodies to enhance ultrasound imaging and HIFU treatment effects.

Benefits of technology

Through targeted microvesicles, the ablation effect of HIFU treatment is enhanced, the risk of damage to normal tissues is reduced, the effect of liver cancer treatment is improved, and the anti-tumor immune response is activated.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074957A_ABST
    Figure CN119074957A_ABST
Patent Text Reader

Abstract

The invention discloses a targeted microbubble for sensitizing high-intensity focused ultrasound and application of the targeted microbubble, and belongs to the technical field of medicines.The targeted microbubble is prepared through the following steps that S1, a lipid shell of polyethylene glycol, phospholipid and fatty acid and the interior of the lipid shell are filled with perfluorobutane to prepare a freeze-dried microbubble; and S2, reconstructing the freeze-dried microbubble in 1mL of sterile normal saline (0.9% sodium chloride), and incubating with a biotinylated antibody to prepare the targeted microbubble. By using the target microbubble enhanced USMI, not only can accurate ultrasonic imaging be provided to guide targeted therapy, but also the ablation effect of HIFU therapy can be effectively amplified, so that the therapeutic effect is improved. The targeted microbubble provided by the invention is used for enhancing the treatment effect of HIFU on liver cancer, and the microbubble widely researched in ultrasonic molecular imaging diagnosis enters a clinical or preclinical stage, so that the difficulty of clinical transformation is greatly reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and in particular relates to a targeted microbubble for enhancing the sensitivity of high-intensity focused ultrasound and an application thereof. Background Art

[0002] HIFU is a minimally invasive, image-guided, adaptable, and repeatable treatment for malignant tumors based on thermal and mechanical ablation. Its safety and effectiveness have been demonstrated in numerous clinical trials of liver cancer patients. However, during HIFU treatment, when the tumor is located deep or has a rich blood supply, the ultrasound energy will attenuate, and higher ultrasound output power is required to eliminate the tumor to the greatest extent, but there is also a risk of damaging normal tissue. In addition, as the main guidance and monitoring method during HIFU treatment, ultrasound also faces the challenge of poor imaging quality. Summary of the invention

[0003] In view of this, the purpose of the present invention is to provide a targeted microbubble for sensitizing high-intensity focused ultrasound and its application, so as to solve the technical problems of incomplete tumor ablation and damage to normal tissue caused by high-power high-intensity focused ultrasound treatment in clinical practice.

[0004] In order to achieve the above object, the present invention provides the following technical solutions:

[0005] The present invention discloses a targeting microbubble for enhancing the sensitivity of high-intensity focused ultrasound. The targeting microbubble is prepared by the following steps:

[0006] S1, firstly prepare freeze-dried microbubbles with a lipid shell of polyethylene glycol, phospholipids and fatty acids and an internal filling of perfluorobutane;

[0007] S2. The freeze-dried microbubbles were reconstituted in 1 mL of sterile physiological saline (0.9% sodium chloride) and incubated with biotinylated antibodies to obtain targeted microbubbles.

[0008] Furthermore, the incubation process in step S2 is as follows: 6ug biotinylated antibody is incubated with 5×10 7 The streptavidin-coated lyophilized microbubbles were incubated together at room temperature for 10 minutes.

[0009] Furthermore, the targeted microbubbles are used to enhance the therapeutic effect of high-intensity focused ultrasound on liver cancer.

[0010] The beneficial effects of the present invention are:

[0011] 1. The present invention utilizes targeted microbubble-enhanced USMI, which can not only provide accurate ultrasound imaging to guide targeted therapy, but also effectively amplify the ablation effect of HIFU therapy, thereby improving the therapeutic effect.

[0012] 2. The targeted microbubbles of the present invention enhance the therapeutic effect of HIFU on liver cancer. Microbubbles, which have been widely studied in ultrasonic molecular imaging diagnosis, have entered the clinical or preclinical stage, greatly reducing the difficulty of clinical transformation.

[0013] Other advantages, objectives and features of the present invention will be described in the following description and will be apparent to those skilled in the art to some extent, or those skilled in the art may be taught from the practice of the present invention. The objectives and other advantages of the present invention may be realized and obtained through the following description. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] In order to make the purpose, technical solution and beneficial effects of the invention clearer, the present invention provides the following drawings for illustration:

[0015] Figure 1 A is a laser scanning confocal microscope (LSCM) image of the microbubble of the present invention and the microbubble linked to the FITC-labeled secondary antibody;

[0016] Figure 1 B is a flow cytometry analysis result of the connection efficiency between FITC and microbubbles of the present invention;

[0017] Figure 2 A is the tumor ultrasound molecular imaging image of T-MBs and I-MBs in vivo of the present invention;

[0018] Figure 2 B is the result of grayscale quantitative analysis of A of the present invention (n=5, **p<0.01);

[0019] Figure 3 A is the real-time ultrasound image of the present invention before and after 2 seconds of 70W, 90W, and 110W HIFU irradiation of the tumor;

[0020] Figure 3 B is the result diagram of quantitative analysis of A of the present invention (n=3, **p<0.01);

[0021] Figure 4 A is the ultrasound image before and after 70W HIFU irradiation of the present invention;

[0022] Figure 4 B is a quantitative analysis result diagram of A of the present invention (n=5, ***p<0.001, ****p<0.0001);

[0023] Figure 4 C is the in vivo B-ultrasound and CEUS imaging images before and after HIFU irradiation of the present invention;

[0024] Figure 4D is the ablation rate of C of the present invention (n=3, *p<0.05, **p<0.01, ****p<0.0001);

[0025] Figure 4 E is a comparison of H&E, TUNEL (green fluorescence) and PCNA staining images (red fluorescence) of the tumor on day 1 after treatment with the present invention;

[0026] Figure 5 A is the image of tumor-bearing mice on days 0, 2, 4, and 6 after treatment with the present invention;

[0027] Figure 5 B is the result diagram of the tumor growth curve of the present invention (n=5, *p<0.05, ***p<0.001);

[0028] Figure 5 C is a graph showing the change in the mouse survival curve (n=5) of the present invention;

[0029] Figure 6 This is a graph showing the weight changes of mice after treatment according to the present invention;

[0030] Figure 7 This is a graph showing the detection results of a cytokine in the serum samples of each group of mice of the present invention;

[0031] Figure 8 Another cytokine detection result diagram in each group of mouse tumor samples of the present invention;

[0032] Fig. 9 A is an immunofluorescence analysis diagram of HSP70 of the present invention;

[0033] Fig. 9 B is an immunofluorescence analysis diagram of CRT of the present invention;

[0034] Fig.10 This is an immunofluorescence analysis diagram of CD8+T cells in tumor tissues of the present invention;

[0035] Fig.11 A is an immunofluorescence analysis of M1 cells in tumor tissues of the present invention;

[0036] Fig.11 B is an immunofluorescence analysis diagram of M2 cells in tumor tissue of the present invention. DETAILED DESCRIPTION

[0037] A targeted microbubble for sensitizing high-intensity focused ultrasound and its application.

[0038] The targeting microbubbles for enhancing the sensitivity of high-intensity focused ultrasound are prepared by the following steps:

[0039] S1, firstly prepare freeze-dried microbubbles with a lipid shell of polyethylene glycol, phospholipids and fatty acids and an internal filling of perfluorobutane;

[0040] S2. The freeze-dried microbubbles were reconstituted in 1 mL of sterile physiological saline (0.9% sodium chloride) and incubated with biotinylated antibodies to obtain targeted microbubbles.

[0041] Targeted microbubbles are used to enhance the therapeutic effect of high-intensity focused ultrasound on liver cancer.

[0042] The test steps are as follows:

[0043] S1. Establish mouse tumor model;

[0044] S2, preparing targeted microbubbles;

[0045] S3, in vivo ultrasound molecular imaging;

[0046] S4, optimize sound power;

[0047] S5, MBs enhance the therapeutic effect of HIFU ablation;

[0048] S6. Monitor immune response;

[0049] S7. Analysis results.

[0050] In step S1: at 5% CO 2 H22 hepatoma cell line was cultured in RPMI1640 medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C. Subcutaneous hepatoma tumors were established in 6-8 week old male Balb / c mice. H22 cells in logarithmic growth phase were collected, centrifuged and resuspended in PBS, and 1×10 cells were injected subcutaneously into the base of the right hind leg of each mouse. 6 After about 10 days, when the tumor size reaches about 80 mm 3 At , mice were randomized to undergo ultrasound imaging or treatment;

[0051] In step S2, freeze-dried microbubbles are first prepared from a lipid shell of polyethylene glycol, phospholipids and fatty acids and filled with perfluorobutane, and then the freeze-dried microbubbles are reconstituted in 1 mL of sterile saline (0.9% sodium chloride) and incubated with biotinylated antibodies to prepare targeted microbubbles.

[0052] Then, 6ug of biotinylated antibody was mixed with 5×10 7 The streptavidin-coated lyophilized microbubbles were incubated together at room temperature for 10 minutes; the lyophilized microbubbles were respectively combined with biotinylated anti-B7-H3 antibodies and isotype control antibodies to obtain B7-H3 targeting microbubbles (T-MBs) and isotype control microbubbles (I-MBs).

[0053] In step S3, ultrasound imaging was performed on the 10th day after tumor inoculation; 10 mice were randomly divided into two groups, and each group was intravenously injected with 50 μL of microbubble suspension: T-MBs and I-MBs;

[0054] Mouse tumors were imaged using a clinical ultrasound system equipped with a PLI-1205BX transducer, using both B-mode (frequency: 6.0 MHz, MI 0.04) and contrast-enhanced mode (frequency: 5.5 MHz, MI 0.09) in the largest cross-section;

[0055] After microbubble injection, an 8-min observation period was performed, and time-intensity curves (TICs) were generated based on the quantitative analysis of contrast signals; ultrasound contrast images of T-MBs and I-MBs were captured and compared at different time points; and ultrasound grayscale values ​​were measured using DFY software.

[0056] In step S4, the present invention uses a HIFU system including a therapeutic and diagnostic ultrasound unit;

[0057] The focal length of the therapeutic transducer is 140 mm, the diameter is 220 mm, and the operating frequency is 0.94 MHz; the focal area is 9.8 mm long along the beam axis and 1.3 mm wide laterally; the diagnostic transducer is located at the center of the therapeutic transducer, and the center frequency range is 3.5-5 MHz;

[0058] To observe the immediate ablation effect of HIFU and optimize the acoustic power, tumor-bearing mice were randomly divided into six groups and received different treatments, including HIFU alone (70 W, 90 W, 110 W) and I-MBs + HIFU (70 W, 90 W, 110 W);

[0059] After the mice were anesthetized with 1% sodium pentobarbital, the tumors were irradiated with ultrasound at different acoustic powers under ultrasound guidance for 2 seconds. The ablation effect was confirmed and compared based on the grayscale changes (GSCs) during the treatment process.

[0060] GSCs mainly reflect the difference in echo signals in the tumor area before and after HIFU treatment. In order to minimize the complications caused by thermal effects, the minimum acoustic power that causes GSCs representing tissue coagulative necrosis was optimized for use in subsequent experiments.

[0061] In step S5, in order to verify the therapeutic effect of MBs-enhanced HIFU, the tumor-bearing mice were divided into four groups: a control group, a simple HIFU group, an I-MBs+HIFU group, and a T-MBs+HIFU group;

[0062] To emphasize the role of T-MBs in enhancing HIFU ablation efficiency, the tumor was sonicated using the optimized acoustic power at the fourth minute after MBs injection;

[0063] On the first day after treatment, 50 μL of Sonovue microbubbles were injected for ultrasound contrast imaging to evaluate tumor blood perfusion; the long (L) and short (S) diameters of the tumor and the non-enhanced area within the tumor were measured on ultrasound images using ImageJ software;

[0064] The volume of the tumor and non-enhanced area was calculated using the formula: Volume (mm^3) = L × S^2 × π / 6; the ablation rate (%) was calculated as follows: (non-enhanced volume after treatment - non-enhanced volume before treatment) / (tumor volume - non-enhanced volume before treatment);

[0065] Subsequently, the tumors were fixed with 4% paraformaldehyde and subjected to hematoxylin and eosin (H&E), proliferating cell nuclear antigen (PCNA), and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) immunofluorescence staining;

[0066] The long (L) and short (S) diameters of the tumor were measured with a vernier caliper every two days for two weeks, and the tumor size was estimated using the formula: L×S^2×π / 6. The survival of the mice was observed.

[0067] In step S6, in order to study the immune response induced by HIFU, mice were killed on the 1st, 3rd and 7th days after receiving control, HIFU alone, I-MBs+HIFU and T-MBs+HIFU treatments, respectively;

[0068] On day 1, the expression of heat shock protein 70 (Hsp70) and calreticulin (CRT) in tumor tissues was determined by immunofluorescence assay; the main monoclonal antibodies (mAbs) used for immunofluorescence assay included anti-Hsp70 and anti-CRT;

[0069] On days 1, 3, and 7, cytokine levels in mouse serum and tumor tissues, including interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-10 (IL-10), were quantified using ELISA kits; tumor tissue sections were immunofluorescently stained using mouse-specific fluorescent dye-conjugated monoclonal antibodies (mAbs), including CD8, CD86, and CD206 antibodies, to observe the infiltration of CD8+ T cells, M1, and M2 macrophages in tumor tissues; the stained slides were scanned using an upright fluorescence microscope, and digital images were viewed using an imaging system.

[0070] In step S7, GraphPad Prism 9 software was used for statistical analysis, and the results were expressed as mean ± standard deviation;

[0071] One-way ANOVA was used for analyses involving three or more groups, followed by Tukey correction for multiple hypotheses in GraphPad Prism;

[0072] The differences between the two groups were analyzed by unpaired t test with unequal variances;

[0073] P values ​​less than 0.05 were considered significant;

[0074] The Kaplan-Meier method in GraphPad Prism was used to determine the probability of survival in animal studies.

[0075] result:

[0076] Regarding in vivo ultrasound molecular imaging, e.g. Figure 1 A and Figure 1 As shown in Figure B, the binding efficiency of T-MBs and anti-B7-H3 antibody was 99.5%; after injection of T-MBs or I-MBs, ultrasound imaging showed that the tumor rapidly enhanced during the perfusion period, as shown in Figure 2. Figure 2 A usually occurs about 3 seconds after injection.

[0077] Figure 2 The time-intensity analysis shown in B revealed a significant difference between I-MBs and T-MBs in the time to reach peak intensity, at 9 and 30 seconds, respectively; and during the regression period, I-MBs showed a significantly faster signal decline compared with T-MBs; by the fourth minute after injection, the I-MBs signal had mostly dissipated within the tumor region, while the T-MBs signal was still 4.6 times higher than the former;

[0078] The results showed that at this time, T-MBs had successfully bound to the B7-H3 site that was highly expressed on the tumor neovascular endothelium, so that four minutes after injection, T-MBs accumulated in the tumor area, providing an advantage for subsequent enhanced HIFU treatment.

[0079] Gray scale changes (GSC) are considered as a sign of successful tumor tissue ablation. Figure 3 A and Figure 3 As shown in Figure 2 (B), when the intensity of HIFU treatment was 90 W and 110 W, the grayscale increased rapidly and significantly even without the injection of I-MBs; but only when combined with I-MBs did HIFU induce significant GSC at an intensity of 70 W, indicating that the use of microbubbles enhanced the ablation effect on tumors; lower acoustic power helped to improve safety during HIFU treatment; based on the above analysis, a power intensity of 70 W and a duration of 2 seconds were selected as the optimization scheme for subsequent microbubble-enhanced HIFU experiments.

[0080] Further evaluation of the ability of T-MBs to enhance HIFU ablation was consistent with the results of ultrasound molecular imaging, such as Figure 4 A and Figure 4 As shown in B, HIFU treatment was performed four minutes after microbubble injection, and T-MBs+HIFU treatment induced more significant GSCs compared with I-MBs+HIFU;

[0081] Ultrasound imaging showed that tumors treated with HIFU showed reduced blood perfusion and varying degrees of filling defects; Figure 4 As shown in C, T-MBs+HIFU resulted in the most obvious filling defect. Further quantitative analysis showed that Figure 4 As shown in D, the non-enhanced area in the T-MBs+HIFU group was significantly increased compared with the other groups; this enlarged ablation area emphasizes the potential of T-MBs to enhance the efficacy of HIFU ablation.

[0082] like Figure 4 As shown in E, HE staining of the T-MBs+HIFU group showed that the tumor cell structure was significantly destroyed, accompanied by nuclear fragments; PCNA and TUNE staining analysis showed that the red signal associated with cell proliferation was the weakest in the T-MBs+HIFU group, while the green fluorescence signal associated with cell death was the strongest.

[0083] Based on the immediate ablation effect of HIFU, we further explored the synergistic anti-tumor effect of combining HIFU with microbubbles. Figure 5 As shown in A, the I-MBs+HIFU group showed a slowed tumor growth rate, while the tumor gradually regressed after T-MBs+HIFU treatment; Figure 5 As shown in B, comparison of tumor volumes 14 days after treatment clearly shows that tumors treated with T-MBs+HIFU were significantly smaller than those treated with HIFU alone.

[0084] Figure 6 As shown, there was no significant change in the body weight of mice during the entire observation period;

[0085] like Figure 5 As shown in C, the survival curve data showed that the survival time of mice was significantly prolonged after T-MBs+HIFU treatment;

[0086] The above findings demonstrate that the combination of T-MBs and HIFU can produce a synergistic antitumor effect, thereby prolonging the survival of the HCC tumor model.

[0087] The changes in cytokine levels in mice were evaluated 1, 3, and 7 days after HIFU treatment. Figure 7As shown in the figure, on the first day after HIFU treatment, serum IFN-γ, TNF-α, and IL-6 were significantly increased, while IL-10 was significantly decreased in the T-MBs+HIFU group compared with the control group and the simple HIFU group; no significant changes in serum cytokine levels were observed on the 3rd and 7th days after HIFU treatment, indicating that HIFU treatment may have triggered an acute systemic inflammatory response that gradually subsided over time;

[0088] The response at the tumor site lags behind the rapid response in serum, e.g. Figure 8 As shown in the figure, no significant changes in tumor cytokine levels were detected on day 1 after HIFU treatment; on day 3 after treatment, the tumor IFN-γ, TNF-α, and IL-6 levels in the T-MBs+HIFU group increased compared with the control group; on day 7 after treatment, the increase in IFN-γ, TNF-α, and IL-6 continued, while the IL-10 level in the T-MBs+HIFU group decreased. The cytokine levels in the tumor gradually increased from day 1 to day 7 after HIFU treatment, indicating that the immune response was staged infiltration.

[0089] To investigate the anti-tumor immune response induced by T-MBs and HIFU, immunofluorescence staining was performed on tumor samples. Fig. 9 As shown in A, HIFU treatment alone resulted in a significant increase in Hsp70 fluorescence intensity, indicating a strong thermal effect. In contrast, the I-MBs+HIFU group showed moderate fluorescence intensity, while the T-MBs+HIFU group showed the lowest intensity. These findings demonstrate the different degrees of thermal effect induced by HIFU under different conditions, emphasizing the enhanced mechanical effect of T-MBs. Fig. 9 As shown in B, significant CRT expression was observed after T-MBs or I-MBs+HIFU treatment, especially in the former group. In contrast, HIFU alone had minimal effect on CRT expression.

[0090] exist Fig.10 In the study, significant CD8+T cell infiltration was found in tumors treated with T-MBs or I-MBs+HIFU, and increased over time. In addition, CD8+T cell infiltration was more significant in the T-MBs+HIFU group compared with the I-MBs+HIFU group, while only weak CD8+T cell infiltration was observed after HIFU treatment alone. M1 macrophages also showed a similar trend, such as Fig.11 As shown in A. In contrast, the number of M2 macrophages in tumor tissues showed a downward trend after treatment, and the T-MBs+HIFU group showed the least M2 macrophages, as shown in Fig.11 B. Based on these results, we can speculate that T-MBs+HIFU treatment most effectively activated the anti-tumor immune response.

[0091] In summary, targeted microbubbles achieved liver cancer-specific ultrasound molecular imaging by targeting vascular endothelial B7-H3 receptors; T-MBs effectively enhanced the effect of HIFU in tumor ablation.

[0092] Compared with HIFU alone and I-MBs+HIFU treatment, T-MBs+HIFU treatment showed better tumor ablation and growth inhibition effects, and triggered a gradually enhanced anti-tumor immune response. The present invention provides a valuable preclinical research basis for the clinical transformation of targeted microbubbles combined with HIFU for tumor treatment.

[0093] Finally, it should be noted that the above preferred embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail through the above preferred embodiments, those skilled in the art should understand that various changes can be made in form and details without departing from the scope defined by the claims of the present invention.

Claims

1. A targeted microbubble for sensitizing high-intensity focused ultrasound, characterized in that: The targeting microbubbles are prepared by the following steps: S1, firstly prepare freeze-dried microbubbles with a lipid shell of polyethylene glycol, phospholipids and fatty acids and an internal filling of perfluorobutane; S2. The freeze-dried microbubbles were reconstituted in 1 mL of sterile physiological saline and incubated with biotinylated antibodies to obtain targeted microbubbles.

2. The targeted microbubble for enhancing high intensity focused ultrasound according to claim 1, characterized in that: The incubation process in step S2 is as follows: 6ug biotinylated antibody is mixed with 5×10 7 The streptavidin-coated lyophilized microbubbles were incubated together at room temperature for 10 minutes.

3. A targeted microbubble for enhancing high intensity focused ultrasound sensitivity according to claims 1-2, characterized in that: The targeted microbubbles are used for sensitizing high-intensity focused ultrasound in the treatment of liver cancer.